Archive

« Older Entries

LSP portfolio company Pharvaris B.V. announced a $66 mln Series B round Wednesday, September 11th, 2019
Pharvaris Announces $66 Million Series B Financing to Advance the Clinical Development of an Oral Therapy for Hereditary Angioedema   Pharvaris has initiated its first-in-human clinical trial of PHA121 Seri [...]
Immunic, Inc.'s Interim Dosing Analysis of IMU-838 as Part of its Ongoing Phase 2 CALDOSE-1 Study in Patients with Moderate-to-Severe Ulcerative Colitis Es... Friday, September 6th, 2019
– Unblinded Data Review Committee Recommended Continuation of the Lowest, 10 mg Dose as well as the Highest, 45 mg Dose –   – Company Now Plans to Continue Study with All Three Dosing Arms – [...]
LSP joins as new investor in Nkarta Therapeutics in it's series B finanancing Friday, September 6th, 2019
Nkarta Therapeutics Raises $114 Million in Series B Financing to Advance Multiple Programs into Clinical Trials   SOUTH SAN FRANCISCO, Calif. – September 4, 2019 – Nkarta Therapeutics, a privately-held bi [...]
LSP leads EUR 40 million Series C funding in iSTAR Medical Thursday, September 5th, 2019
Amsterdam, the Netherlands — 5 September 2019: LSP, one of Europe’s leading life sciences and healthcare investors, today announced its investment in iSTAR Medical SA, a Belgian private medical device company deve [...]
Kuros Biosciences Announces U.S. FDA approval of IND Application to Initiate Fibrin-PTH Phase 2a Clinical Trial in Spinal Fusion Tuesday, September 3rd, 2019
Kuros to conduct Phase 2a trial in spinal fusion, comparing Fibrin-PTH to autograft Primary endpoint is radiographic interbody fusion at 12 months   Schlieren (Zurich), Switzerland, September 3, 2 [...]
Immunic, Inc. Announces First Patient Enrolled in Investigator-Sponsored Proof-of-Concept Clinical Trial of IMU-838 for the Treatment of Patients with Prim... Monday, August 12th, 2019
– Study Being Conducted in Collaboration with Investigators at Arizona State University and the Mayo Clinic –    SAN DIEGO, Aug. 12, 2019 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage bi [...]
LSP portfolio company Binx Health to receive 510(k) marketing authorization for its io- system Monday, August 12th, 2019
binx io enables first-ever “test-and-treat” paradigm with sample to answer in 30 minutes for the two most tested-for sexually transmitted infections (STIs)   August 12, 2019 (BOSTON) PR NEWSWIRE – binx [...]
ImCheck Therapeutics Awarded €2 Million from Bpifrance to Advance its First-in-Class Immunotherapy Program into the Clinic Thursday, August 1st, 2019
Bpifrance views ImCheck’s projects as unique and well-positioned Marseille, France, August 1, 2019 – ImCheck Therapeutics, a biotech companyon the cutting edge of the next wave of immunotherapies agains [...]
Immunic AG Awarded Research Grant by German Federal Ministry of Education and Research in Support of the InnoMuNiCH Project Thursday, August 1st, 2019
SAN DIEGO, Aug. 1, 2019 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing potentially best-in-class, oral therapies for the treatment of chronic inflammator [...]
LSP leads €67m [$75m] Series A financing in Alizé Pharma 3 Wednesday, July 31st, 2019
Significantly oversubscribed financing round with an LSP-led international syndicate of investors. Proceeds will be used to grow Alize Pharma 3’s team in Lyon and Boston, to advance its current programs in [...]

« Older Entries

2019
2018
2017
2016
2015
2014
2013
2012
back to archive overview
Follow us

Archive

« Older Entries

LSP portfolio company Pharvaris B.V. announced a $66 mln Series B round Wednesday, September 11th, 2019
Pharvaris Announces $66 Million Series B Financing to Advance the Clinical Development of an Oral Therapy for Hereditary Angioedema   Pharvaris has initiated its first-in-human clinical trial of PHA121 Seri [...]
Immunic, Inc.'s Interim Dosing Analysis of IMU-838 as Part of its Ongoing Phase 2 CALDOSE-1 Study in Patients with Moderate-to-Severe Ulcerative Colitis ... Friday, September 6th, 2019
– Unblinded Data Review Committee Recommended Continuation of the Lowest, 10 mg Dose as well as the Highest, 45 mg Dose –   – Company Now Plans to Continue Study with All Three Dosing Arms – [...]
LSP joins as new investor in Nkarta Therapeutics in it's series B finanancing Friday, September 6th, 2019
Nkarta Therapeutics Raises $114 Million in Series B Financing to Advance Multiple Programs into Clinical Trials   SOUTH SAN FRANCISCO, Calif. – September 4, 2019 – Nkarta Therapeutics, a privately-held bi [...]
LSP leads EUR 40 million Series C funding in iSTAR Medical Thursday, September 5th, 2019
Amsterdam, the Netherlands — 5 September 2019: LSP, one of Europe’s leading life sciences and healthcare investors, today announced its investment in iSTAR Medical SA, a Belgian private medical device company deve [...]
Kuros Biosciences Announces U.S. FDA approval of IND Application to Initiate Fibrin-PTH Phase 2a Clinical Trial in Spinal Fusion Tuesday, September 3rd, 2019
Kuros to conduct Phase 2a trial in spinal fusion, comparing Fibrin-PTH to autograft Primary endpoint is radiographic interbody fusion at 12 months   Schlieren (Zurich), Switzerland, September 3, 2 [...]
Immunic, Inc. Announces First Patient Enrolled in Investigator-Sponsored Proof-of-Concept Clinical Trial of IMU-838 for the Treatment of Patients with Pr... Monday, August 12th, 2019
– Study Being Conducted in Collaboration with Investigators at Arizona State University and the Mayo Clinic –    SAN DIEGO, Aug. 12, 2019 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage bi [...]
LSP portfolio company Binx Health to receive 510(k) marketing authorization for its io- system Monday, August 12th, 2019
binx io enables first-ever “test-and-treat” paradigm with sample to answer in 30 minutes for the two most tested-for sexually transmitted infections (STIs)   August 12, 2019 (BOSTON) PR NEWSWIRE – binx [...]
ImCheck Therapeutics Awarded €2 Million from Bpifrance to Advance its First-in-Class Immunotherapy Program into the Clinic Thursday, August 1st, 2019
Bpifrance views ImCheck’s projects as unique and well-positioned Marseille, France, August 1, 2019 – ImCheck Therapeutics, a biotech companyon the cutting edge of the next wave of immunotherapies agains [...]
Immunic AG Awarded Research Grant by German Federal Ministry of Education and Research in Support of the InnoMuNiCH Project Thursday, August 1st, 2019
SAN DIEGO, Aug. 1, 2019 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing potentially best-in-class, oral therapies for the treatment of chronic inflammator [...]
LSP leads €67m [$75m] Series A financing in Alizé Pharma 3 Wednesday, July 31st, 2019
Significantly oversubscribed financing round with an LSP-led international syndicate of investors. Proceeds will be used to grow Alize Pharma 3’s team in Lyon and Boston, to advance its current programs in [...]

« Older Entries

2019
2018
2017
2016
2015
2014
2013
2012
back to archive overview